| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer | Chief Executive Officer | Director
3 companies
Gary S Jacob is Chief Development Officer at OKYO, with reported holdings spanning 3 companies. Gary S Jacob's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $184K at current prices.
Gary S Jacob's largest disclosed position is in OKYO as Chief Development Officer, worth about $163K. Net of sales, the OKYO filings show accumulation of 12,500 shares.
Gary S Jacob has 22 Form 4 filings on record from March 2015 to July 2026, across 3 companies: Chief Development Officer at OKYO Pharma (OKYO), 2022–2026; Director at Hepion Pharmaceuticals (HEPA), 2016–2024; Former Director at Cardiff Oncology (CRDF), 2015–2021.
The 31 reported transactions were 13 option or other derivative awards, 8 other transactions, 7 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $120K and no sales.
The largest open-market purchase was 12,500 shares of OKYO at an average $4.00 on May 19, 2022, about $50K. Twelve months later OKYO was down 53%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | OKYO Okyo Pharma Ltd | Chief Executive Officer | Buy | 12,500 | $4.00 | $50,000.00 | New | -32.1% | -53.2% | |
| Mar 23, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 2,370 | $10.42 | $24,689.35 | +12.1% | -22.3% | -75.7% | |
| Dec 1, 2020 | HEPA Hepion Pharmaceuticals, Inc. | Director | Buy | 12,000 | $1.66 | $19,920.00 | +20,339% | - | - | |
| May 14, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 17,483 | $1.43 | $25,000.69 | +845.0% | - | - |